On June 12, Hengrui Medicine (01276.HK) rose 3.43% in regular trading, trading at HKD 54.2/share, with turnover of HKD 77.47 million.

On the news front, multiple catalysts continue to drive sentiment recovery. Most recently, the company's self-developed IFNAR1/TACI antibody fusion protein SHR-2173 for systemic lupus erythematosus presented Phase I clinical results at the EULAR annual meeting held in London. The study demonstrated favorable safety with no treatment-emergent adverse events leading to trial discontinuation, providing important evidence for continued development.

Additionally, three new drugs — HRS-6209 (selective CDK4 inhibitor), HRS-8080 (oral estrogen receptor degrader), and HRS-9813 (first-in-class candidate) — received clinical trial approvals on June 9. The company also maintained its buyback program, repurchasing a cumulative 67.4 thousand A-shares over June 8-11 totaling approximately RMB 31.11 million. Full-year revenue reached RMB 31.63 billion with net profit of RMB 7.71 billion, up 21.69% year-over-year, reinforcing fundamental improvement signals.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)